Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Diabetes / Metabolic Women's Health Rheumatology Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Clinical Trial ● Currently Recruiting Non-phase study NCT06891755

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung – Study 3

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung – Study 3 — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT06891755.

📅 06 Apr 2026 ⏱ 2 min read
Currently Recruiting
This trial is actively seeking participants in the UK. Discuss eligibility with your patient before referring.
Status
Currently Recruiting
Phase
Non-phase study
NCT ID
NCT06891755
Sponsor
Apreo Health, Inc.
Start
2025-07-15
ClinicaliQ Trial Snapshot
  • Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung – Study 3 — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT06891755.
  • The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite….
  • Sponsor: Apreo Health, Inc.

Verify eligibility, endpoints and current status on the original source registry before acting on this summary.

Use This Page For
  • Quick orientation before opening the registry record.
  • Checking recruitment status, phase and sponsor at a glance.
  • Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying

The objective of this study is to assess the safety and efficacy of Apreo BREATHE system when used to support native airways and release trapped air in the treatment of adult COPD patients with emphysema suffering from dyspnea due to hyperinflation despite optimal medical treatment. The Apreo BREATHE Airway Scaffold is a permanent implant designed to tent open native airways. The study will include up to 250 participants at up to 25 study centers located in the United States and Europe. Study subjects will be followed for 3 years. The…

Eligibility Snapshot
  • Subject is at least 40, but not older than 84, years of age.
  • Subject has body mass index (BMI) of between 18 and 32, inclusive.
  • Subject has completed a documented pulmonary rehabilitation program within 12 months prior to Baseline.
  • Subject has mMRC score ≥ 2.
  • Subject can walk ≥100 meters in 6 minutes.

Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.

Full Trial Details
View this trial on the source registry
Eligibility criteria, protocol, and results when available
View Trial ↗
Share: Twitter/X LinkedIn
Related

Related Clinical Intelligence

Guidelines, Drug Science, safety briefs and education connected to this trial area.

Guideline
XVIVO Perfusion System (ex-situ machine perfusion) for assessing and reconditioning marginal lungs for transplantation: early-use assessment
Respiratory / COPD / Asthma · 21 Oct 2026
XVIVO Perfusion System enables ex-situ assessment of marginal donor lungs before transplantation, allowing objective evaluation of organ viability and function to improve…
View guideline →
Clinical Brief
Over one million children referred for mental healthcare – with anxiety the main reason
Respiratory / COPD / Asthma · BBC Health · 29 Jun 2026
Over one million children in England have been referred for mental healthcare, with anxiety as the leading presenting complaint, indicating a substantial…
View brief →
Guideline
Brensocatib for treating non-cystic fibrosis bronchiectasis in people 12 years and over (terminated evaluation)
Respiratory / COPD / Asthma · 25 Aug 2026
Evaluation terminated: Brensocatib for non-CF bronchiectasis is no longer under NICE appraisal—do not initiate new treatment pathways for this indication pending alternative…
View guideline →
Clinical Brief
RSV vaccination: expansion of eligibility to older adults in certain clinical risk groups
Respiratory / COPD / Asthma · NHS England · 01 Jul 2026
From September 2026, RSV vaccination eligibility expands beyond the current age-based criteria to include older adults in specific clinical risk groups, requiring…
View brief →
Clinical Brief
Mum told to ‘prepare for worst’ urges others to get respiratory illness vaccine
Respiratory / COPD / Asthma · BBC Health · 13 Oct 2026
RSV vaccination in pregnancy is now available and recommended; Jo Goldsmith's case highlights the clinical value of preventing severe respiratory syncytial virus…
View brief →
Clinical Brief
There’s a reason child vaccination rates are falling – and it’s not social media
Respiratory / COPD / Asthma · BBC Health · 03 Aug 2026
Vaccination rates declining across UK: Child immunisation coverage is falling below safe thresholds needed for herd immunity, creating vulnerability to vaccine-preventable disease…
View brief →